A2A Pharmaceuticals
Clinical-stage drug discovery company that applies AI-driven computational design to discover and advance small-molecule therapeutics for oncology, antibiotic resistance, and muscular dystrophy. Operates a proprietary computational platform for target-specific small-molecule library generation, iterative optimization, and ADMET filtering; runs preclinical validation (including PDX and organoid models) and has advanced at least one protein-protein interaction inhibitor into human Phase 1 testing and completed IND interactions with regulators.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Clinical-stage PPI inhibitor targeting TACC3
A first-in-class small-molecule inhibitor of the TACC3 protein–protein interaction advanced into Phase 1 dose-escalation studies in ovarian, triple-negative breast, and endometrial cancer, with reported tumor reductions and ongoing dose expansion planning.
MLL–Menin interaction inhibitors (clinically advanced via spinout)
Small molecules designed to disrupt the menin–MLL interaction for genetically defined leukemias and select solid tumors; program progressed into clinical development via a spinout company.
TYK2 pseudokinase selective inhibitor (preclinical)
Small-molecule program targeting the TYK2 pseudokinase domain to modulate specific cytokine signaling with the aim of improved safety for chronic autoimmune indications.
YAP–TEAD inhibitor / degrader program (preclinical)
Program developing inhibitors and degraders that disrupt the YAP–TEAD transcriptional complex, designed to address YAP-driven oncogenic processes.
KRAS degrader program (preclinical)
Development of degrader-based approaches intended to target a broad spectrum of KRAS mutations rather than mutation-specific inhibitors to address a larger patient population.
SCULPT therapeutic design platform (service/platform)
Proprietary platform implementing systematic combinatorial unification of chemical groups, target-specific design, optimization iterations, and ADMET filtering to advance small-molecule candidates.
Clinical-stage PPI inhibitor targeting TACC3
A first-in-class small-molecule inhibitor of the TACC3 protein–protein interaction advanced into Phase 1 dose-escalation studies in ovarian, triple-negative breast, and endometrial cancer, with reported tumor reductions and ongoing dose expansion planning.
MLL–Menin interaction inhibitors (clinically advanced via spinout)
Small molecules designed to disrupt the menin–MLL interaction for genetically defined leukemias and select solid tumors; program progressed into clinical development via a spinout company.
TYK2 pseudokinase selective inhibitor (preclinical)
Small-molecule program targeting the TYK2 pseudokinase domain to modulate specific cytokine signaling with the aim of improved safety for chronic autoimmune indications.
YAP–TEAD inhibitor / degrader program (preclinical)
Program developing inhibitors and degraders that disrupt the YAP–TEAD transcriptional complex, designed to address YAP-driven oncogenic processes.
KRAS degrader program (preclinical)
Development of degrader-based approaches intended to target a broad spectrum of KRAS mutations rather than mutation-specific inhibitors to address a larger patient population.
SCULPT therapeutic design platform (service/platform)
Proprietary platform implementing systematic combinatorial unification of chemical groups, target-specific design, optimization iterations, and ADMET filtering to advance small-molecule candidates.
Services
Collaborative discovery and preclinical development using the company's computational platform to design and optimize small-molecule candidates for partner programs.
Custom design of large combinatorial libraries and in silico prioritization for synthesis using iterative computational workflows.
Collaborative discovery and preclinical development using the company's computational platform to design and optimize small-molecule candidates for partner programs.
Custom design of large combinatorial libraries and in silico prioritization for synthesis using iterative computational workflows.
Expertise Areas
- AI-driven computational drug discovery
- Oncology small-molecule development
- Protein–protein interaction inhibitors
- Small-molecule degrader development
Key Technologies
- AI-driven molecular design
- Large combinatorial small-molecule libraries
- Protein–protein interaction (PPI) inhibition
- Small-molecule degrader strategies
News & Updates
Phase 1 dose-escalation progress reported with tumor reductions observed in ovarian, triple-negative, and endometrial cancer cohorts; dose expansion planned.
Announcement referencing regulatory clearance to proceed with IND for a TACC3-targeting PPI inhibitor.
Announcement of a multi-target co-development agreement with an external pharmaceutical company for AI-enhanced oncology discovery.
Reference to the spinout/partner company raising a $56M Series A to advance menin inhibitors into the clinic.
IND for a TACC3-targeting PPI inhibitor was filed and regulatory interactions advanced toward first-in-human studies.
Dosing of first patients in multiple oncology indications as part of Phase 1 dose-escalation.
Phase 1 dose-escalation progress reported with tumor reductions observed in ovarian, triple-negative, and endometrial cancer cohorts; dose expansion planned.
Announcement referencing regulatory clearance to proceed with IND for a TACC3-targeting PPI inhibitor.
Announcement of a multi-target co-development agreement with an external pharmaceutical company for AI-enhanced oncology discovery.
Reference to the spinout/partner company raising a $56M Series A to advance menin inhibitors into the clinic.
IND for a TACC3-targeting PPI inhibitor was filed and regulatory interactions advanced toward first-in-human studies.
Dosing of first patients in multiple oncology indications as part of Phase 1 dose-escalation.